肌萎缩侧索硬化
粒体自噬
SOD1
运动神经元
下调和上调
神经科学
医学
运动功能
线粒体
神经保护
氧化应激
生物
疾病
神经肌肉接头
神经退行性变
药理学
运动协调
运动活动
神经元
帕金
骨骼肌
MFN2型
自噬
氧化磷酸化
品脱1
作者
Bingge Zhang,Ye He,Ting Su,Xiaomei Li,Xiufen Zhang,Ruijuan Liu,Xiao Han,Ruiming Zhang,Chao Yang,Xinlei Liu,Qinghua Hou,Zaijun Zhang,Xie Yongmei,Gongping Liu,Xifei Yang
摘要
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss, skeletal muscle atrophy, paralysis, and eventually death. Mitochondrial dysfunction plays a pivotal role in ALS pathogenesis, although the precise pathogenic mechanisms remain elusive, and effective therapeutic strategies are extremely limited. In this study, we developed a small-molecule inhibitor, UA-30, which directly targets RalA, and explored its potential for the treatment of ALS. We found that when administered via oral gavage for 6 weeks following the onset of motor deficit, UA-30 extended lifespan and improved motor function of SOD1G93A mice, a model of ALS. UA-30 ameliorated motor neuron loss, neuroinflammation, fibrosis, and mitochondrial dysfunction, as evidenced by energy recovery, decreased oxidative stress, and enhanced mitophagy. Mechanistically, UA-30 inhibited RalA activity and thereby modulated ERK/FOXO3a signaling, which inhibited FOXO3a degradation via the ubiquitin-proteasome pathway; enhanced FOXO3a stability; and upregulated the expression of mitophagy-related genes in this ALS mouse model. The beneficial effects of UA-30 in ALS were abolished by overexpression of the constitutively active form of RalA (RalAG23V) or Mdivi-1 treatment. These findings support RalA inhibition as a therapeutic strategy for enhancing mitophagy and mitigating ALS-like pathology and support UA-30 as an orally active candidate for further preclinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI